Of the 25 disability patient groups, 32% represent patient interests to drug regulators. Leading activities include advocating for fair medicine pricing, addressing cost barriers for low-income and vulnerable people and/or equitable access to healthcare (each 18%).
32% of respondents from Disability ‘Regularly’ or ‘Sometimes’ represent patient interests to drug regulators
Patient groups representing each Disability sub-type
25 patient groups across 3 sub-types
The percentages below highlight how the 11 patient groups interact with regulators and advocate for patient interests. As respondents may be represented in more than one area, percentages may not total 100%.
GET THE REPORT
Our research covers 2,262 patient groups representing 100 countries and 45 therapy areas. The sample report shows you the depth of analysis for a single country or therapy area. To access any other reports, please get in touch.
Visit patient-view.com to gather more information or email: Alex Wyke, alexwyke@patient-view.com